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Abstract
Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical
industry’s lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing
for 20 years at a cost in excess of $100 million. To date, gD-2 vaccines have yielded equivocal protection in clinical trials.
Therefore, using a small animal model, we sought to determine if a live-attenuated HSV-2 ICP0
2 virus would elicit better
protection against genital herpes than a gD-2 subunit vaccine. Mice immunized with gD-2 and a potent adjuvant
(alum+monophosphoryl lipid A) produced high titers of gD-2 antibody. While gD-2-immunized mice possessed significant
resistance to HSV-2, only 3 of 45 gD-2-immunized mice survived an overwhelming challenge of the vagina or eyes with wild-
type HSV-2 (MS strain). In contrast, 114 of 115 mice immunized with a live HSV-2 ICP0
2 virus, 0DNLS, survived the same HSV-
2 MS challenges. Likewise, 0DNLS-immunized mice shed an average 125-fold less HSV-2 MS challenge virus per vagina
relative to gD-2-immunized mice. In vivo imaging demonstrated that a luciferase-expressing HSV-2 challenge virus failed to
establish a detectable infection in 0DNLS-immunized mice, whereas the same virus readily infected naı ¨ve and gD-2-
immunized mice. Collectively, these results suggest that a HSV-2 vaccine might be more likely to prevent genital herpes if it
contained a live-attenuated HSV-2 virus rather than a single HSV-2 protein.
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Introduction
Infections with herpes simplex virus 2 (HSV-2) are exceedingly
common; ,1 billion people serve as carriers of HSV-2 and ,20
million people acquire new HSV-2 infections each year [1]. An
effective HSV-2 vaccine would be useful in breaking the cycle, and
protecting young adults from the 1 in 10 chance that they will
acquire HSV-2 before they marry [2,3,4].
Efforts to develop an HSV-2 vaccine have long been predicated
on the assumption that a live-attenuated HSV-2 virus would be
too dangerous to use as a human vaccine. Thus, four types of
vaccines have been most carefully considered: 1. HSV-2 subunit
vaccines [5,6,7,8,9,10]; 2. gene-delivery vehicles that express
HSV-2 proteins [11,12,13,14,15,16,17,18,19]; 3. replication-
defective HSV-2 viruses [20,21,22,23,24,25]; and 4. HSV-2
viruses that are overattenuated and/or unable to replicate in
neurons [26,27,28,29,30,31].
Of these approaches, subunit vaccines based on a combination of
HSV-2 glycoprotein D (gD-2) and a potent adjuvant have received
the greatest level of consideration. The technology to produce
recombinant gD-2 emerged in the early 1980s [32], and the
formulation of gD-2 subunit vaccines has undergone a continual
process of testing and refinement ever since [6,7,11,19,33,34,
35,36,37,38,39,40,41]. Mouse and guinea pig studies have, and
continue, to serve as a testing ground for identifying the optimum
combination of gD-2 immunogen and adjuvant [6,37,38,42]. Two
clinical trials of gD-2 subunit vaccines were completed in the late
1990s and early 2000s [36,41]. In the latter trial, it was noted that
HSV-1 seronegative women responded to a gD-2 subunit vaccine
with significant reductions in the rate of acquiring HSV-2 genital
herpes [36]. These results offered hope that vaccine-induced
protection against HSV-2 genital herpes was possible, but would
need to be further improved.
Mature gD-2 is a 368-amino-acid protein with a hydrophobic
C-terminus. In nature, the gD-2 protein is embedded in the
envelope of HSV-2 virions, and initiates viral entry by attaching to
cell-surface receptors [43]. The recombinant gD-2 protein used in
vaccines lacks the C-terminus, which allows the truncated protein
to be secreted by producer cells [34,35]. Hence, a 302-amino-acid
gD-2 peptide (gD-2302t) is secreted from plasmid-transfected
chinese hamster ovary cells [35], and it has served as the
immunogen in human gD-2 subunit vaccines [36,37,38]. Likewise,
a 306-amino-acid gD-2 peptide (gD-2306t) is secreted from
baculovirus-infected insect cells [34] and exhibits similar immu-
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protein antigen used in gD-2 subunit vaccines has remained
relatively constant over time.
The second critical component of a subunit vaccine is the
adjuvant, which has repeatedly changed in gD-2 subunit vaccine
formulations over the years. In its most recent formulation
[6,37,38], gD-2 subunit vaccines relied on Glaxo Smith Kline’s
‘‘adjuvant system 4’’ (AS04) [44], which means that gD-2 was
absorbed to alum adjuvant and combined with monophosphoryl
lipid A (MPL). MPL is derived from Salmonella minnesota, and
contains a non-toxic analogue of lipid A (a toll-like receptor 4
agonist), which potently activates professional antigen-presenting
cells [45,46]. Hence, MPL drives more potent immune responses
to protein antigens, and was instrumental in the success of the
GardasilH vaccine [47].
Given the acute need for a genital herpes vaccine, the National
Institutes of Allergy and Infectious Disease (NIAID) invested $27.6
million into a gD-2 clinical trial that was conducted from 2003 to
2009 at 48 test sites in the United States [48]. The goal was to
determine if the latest gD-2 subunit vaccine, Glaxo Smith Kline’s
Herpevac/Simpilirix
TM vaccine (gD-2+alum+MPL), would pre-
vent genital herpes in HSV-1 seronegative women. On September
30, 2010, the disappointing results were announced; immunization
with a gD-2 subunit vaccine did not reduce the rate at which
women acquired HSV-2 genital herpes [49]. These results have
left many of the world’s foremost experts questioning how an
immunogen as potent as the gD-2 subunit vaccine could fail to
prevent genital herpes [48].
Theoretical considerations suggest that a gD-2 subunit vaccine
may not elicit the maximum protection against HSV-2 that is
attainable. Ideally, a HSV-2 vaccine would drive clonal expansion
of a broad repertoire of HSV-2-specific B and T cells, and this
diverse subpopulation of lymphocytes would confer complete
resistance to HSV-2 infection. Given that gD-2 is only 1 of 80
HSV-2 proteins, it is unlikely that immunization with gD-2 may
drive clonal expansion of the body’s full repertoire of HSV-2-
specific B and T cells. Thus, we have questioned whether a live-
attenuated HSV-2 virus would better prepare the body’s immune
system to resist HSV-2 infection [50].
Earlier studies of HSV-1 ICP0
2 mutant viruses led us to propose
that mutagenesis of HSV-2’s ICP0 gene might yield viruses that
were interferon-sensitive, avirulent, and suitable for use as a live
HSV-2 vaccine strain [50,51]. We have recently corroborated the
validity of these predictions, and identified a tenable HSV-2
ICP0
2 vaccine strain, HSV-2 0DNLS [52].
Using this novel reagent, the current study was initiated to
determine if mice immunized with the live HSV-2 0DNLS virus were
more resistant to HSV-2 genital herpes than mice immunized with a
gD-2 subunit vaccine. Consistent with previous reports [6,37,38],
mice immunizedwithgD-2306t,alum,and MPLmounted averyhigh
antibody response against gD-2. However, only 3 of 45 gD-2-
immunized mice survived vaginal or ocular challenge with an
overwhelming doseof wild-type HSV-2 MS strain. In contrast, nearly
100% of mice immunized with the HSV-2 ICP0
2 virus, 0DNLS,
survived the same rigorous challenges. Importantly, 0DNLS-
immunized mice were as resistant to superinfection with wild-type
HSV-2 as mice that recovered from a primary infection with wild-
type HSV-2. We present three lines of evidence that mice immunized
with the 0DNLS virus were 10 to 100 times better protected against
HSV-2 genital herpes than mice immunized with a gD-2 subunit
vaccine, similar in composition to the Simpilirix
TM vaccine [48,49].
These results suggest that a HSV-2 vaccine might be more likely to
prevent genital herpes if it contained a live-attenuated HSV-2 virus
rather than a single HSV-2 protein [41,48,53].
Results
HSV-2 0DNLS is avirulent and immunogenic
HSV-2 0DNLS is a live-attenuated virus that is avirulent in mice
following inoculation of the eyes [52]. A test was conducted to
determine if HSV-2 0DNLS was avirulent and immunogenic when
administered to mice by mucosal or subcutaneous routes of
vaccination; namely, the nostrils (mucosal route), rear footpads
(subcutaneous route), or vagina (mucosal route). Wild-type HSV-2
MS (ICP0
+) virus was included as a control to verify that the
0DNLS mutation was necessary to attenuate the pathogenesis of
HSV-2 infection.
Groups of n=10 female ICR mice were inoculated with HSV-2
MS or HSV-2 0DNLS by the following routes: i. 100,000 pfu per
eye; ii. 125,000 pfu per nostril; iii. 500,000 pfu per vagina; or iv.
1,250,000 pfu per rear footpad. Ocular and vaginal swabs
confirmed that HSV-2 MS and 0DNLS consistently replicated in
mice (Fig. S1). HSV-2 MS produced fatal encephalitis in 100% of
mice inoculated in the eyes between Days 6 and 7 post-inoculation
(p.i.), and all intranasally-inoculated mice succumbed by Day 9 p.i.
(Fig. 1A). HSV-2 0DNLS did not produce any overt disease that
was evident upon visual inspection of mice inoculated in the eyes
or nostrils (Fig. 1B). HSV-2 MS inoculation of the vagina of
medoxyprogesterone-treated mice produced lethal disease be-
tween Days 8 and 12 p.i., and death coincided with the onset of
hindlimb paralysis (Fig. 1A). HSV-2 0DNLS did not produce any
overt disease in mice inoculated vaginally (Fig. 1B). Mice
inoculated with HSV-2 MS in the rear footpads were slow to
develop lethal disease, and 50% survived until Day 60 p.i. (Fig. 1A).
HSV-2 0DNLS did not produce any overt disease in mice
inoculated in the rear footpads (Fig. 1B). Thus, the 0DNLS
mutation in the ICP0 gene allowed a mild HSV-2 infection to be
established in ICR mice that did not produce any overt symptoms
of disease following inoculation of the eyes, nose, vagina, or
footpads. However, histological analysis was not performed on
HSV-2 0DNLS-infected tissues, and we cannot exclude the
possibility that HSV-2 0DNLS infection caused pathological
changes that were not visible upon gross examination of
0DNLS-inoculated mice.
HSV-specific IgG antibody levels were compared amongst
0DNLS-inoculated mice and mice surviving footpad inoculation
with HSV-2 MS. Mice were bled on Day 50 p.i., and sera were
tested for the presence of gD-2-specific IgG antibody [34]. MS-
footpad-inoculated mice possessed gD-2 antibody levels that were
an average 100-fold above the background of ELISA (Fig. 1C). All
HSV-2 0DNLS-immunized mice possessed gD-2 antibody levels
that were 25- to 32-fold above background (Fig. 1C). Thus,
regardless of whether mice were inoculated in the eyes, nose, feet,
or vagina, immunization with the live-attenuated HSV-2 0DNLS
virus elicited a significant IgG antibody response directed against
HSV-2’s entry receptor, gD-2.
HSV-2 0DNLS-immunized mice acquire immunity to wild-
type HSV-2
On Day 56 p.i., protective immunity was assessed in the MS-
and 0DNLS-immunized mice described above. In this and all
vaginal challenges, a robust HSV-2 infection was established by 1.
treating mice with 2 mg medoxyprogesterone 7 and 3 days prior
to challenge [54,55], and by 2. inoculating mice with 500,000 pfu
per vagina of wild-type HSV-2 MS. On Days 2, 4, and 6 post-
challenge, naı ¨ve mice shed an average 7900, 1300, and 900 pfu
per vagina, respectively (X symbols in Figs. 2A, 2B). In contrast,
MS-footpad-immunized mice did not shed detectable levels of
HSV-2 challenge virus from their vaginas on Days 2, 4, or 6 post-
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immunized mice shed an average 30- and 220-fold less HSV-2
challenge virus than naı ¨ve mice on Days 2 and 4 (e symbols in
Fig. 2A). On Days 4 and 6 post-challenge, shedding of HSV-2 per
vagina was reduced by .100-fold in all 0DNLS-immunized mice
relative to naı ¨ve controls, regardless of the specific route of
immunization (Fig. 2A, 2B). Likewise, all 0DNLS-immunized mice
survived HSV-2 vaginal challenge regardless of the route of
immunization, whereas 0 of 10 naı ¨ve mice survived HSV-2
vaginal challenge (Fig. 2C).
Mice immunized with HSV-2 0DNLS were also challenged on
Day 56 with 100,000 pfu per eye of wild-type HSV-2 (Fig. S2).
Consistent with the results of vaginal challenge, 0DNLS-immu-
nized mice shed significantly less HSV-2 challenge virus per eye
than naı ¨ve mice on Days 1 and 2 (Fig. S2A, S2B). Likewise, while
0 of 10 naı ¨ve mice survived HSV-2 MS challenge of the eyes, all
0DNLS-immunized mice survived ocular HSV-2 challenge
regardless of the route of 0DNLS immunization (Fig. S2C).
Therefore, mice immunized with HSV-2 0DNLS possessed potent
and systemic protection against wild-type HSV-2.
Footpad immunization with HSV-2 0DNLS versus a gD-2
subunit vaccine
The efficacy of HSV-2 0DNLS-induced protection against
genital herpes was compared to a gD-2 subunit vaccine, similar in
composition to Glaxo Smith Kline’s Simpilirix
TM vaccine
[6,38,48]. Groups of n=40 mice were immunized on Day 0 in
their right, rear footpads with: 1. 2.5 mg gD-2, alum, and 10 mg
monophosphoryl lipid A (MPL); 2. 2.5 mg GFP control antigen,
alum, and 10 mg MPL; 3. culture medium (vehicle); 4. 1610
6 pfu
of HSV-2 0DNLS; or 5. 1610
6 pfu of wild-type HSV-2 MS
(Fig. 3A). Mice inoculated in their rear footpads with wild-type
HSV-2 MS were given 1 mg per ml acyclovir (ACV) in their
drinking water between Days 21 and +20 p.i. to limit the
pathogenesis of the primary infection. Consequently, 100% of
ACV-treated mice survived HSV-2 MS inoculation of the right,
rear footpad (Fig. 3A).
Replication of HSV-2 MS or 0DNLS in the footpads of vaccine
recipients was verified in parallel groups of mice, as follows. In the
absence of ACV, HSV-2 MS replicated to peak titers of 1,000 to
10,000 pfu per footpad on Days 1 and 2 p.i., and viral replication
was low to undetectable thereafter (Fig. 3B). HSV-2 0DNLS
Figure 1. HSV-2 0DNLS is avirulent and immunogenic in female
ICR mice. Duration of survival following inoculation of naı ¨ve mice with
culture medium containing 25,000 pfu per mlo f( A) HSV-2 MS or (B)
HSV-2 0DNLS following placement of 4 ml on left and right scarified
eyes; 5 ml in left and right nostrils; 50 ml in left and right, rear footpads;
or 20 ml instilled into the vaginal vault (n=10 mice per group). A single
asterisk (*) denotes a probability, p, ,0.05 and a double asterisk (**)
denotes p,0.001 that matched pairs of mice inoculated with (A) HSV-2
MS or (B) HSV-2 0DNLS survived at equivalent frequencies, as calculated
by Fisher’s Exact Test. (C) Mean 6 sem abundance of gD-2 specific IgG
antibody in mouse serum on Day 50 p.i., as determined by ELISA on
1:100 dilutions of mouse serum (n=10 per 0DNLS-immunization group;
n=5 MS-immunized mice). The y-axis represents relative units of IgG
abundance expressed as ‘‘fold-increase above background,’’ as deter-
mined relative to a 0.33-log dilution series of high titer anti-HSV-2
antiserum that provided the standard curve that defined the
quantitative relationship between anti-gD-2 IgG antibody abundance
and the colorimetric development in each well of the ELISA plate (i.e.,
the standard curve had a goodness-of-fit of r
2=0.99). A double asterisk
(**) denotes a probability, p, ,0.001 that gD-2-antibody levels were
equivalent to naı ¨ve mice, as determined by one-way ANOVA and
Tukey’s post hoc t-test.
doi:10.1371/journal.pone.0017748.g001
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Days 1 and 2 p.i., which was 30-fold lower than wild-type HSV-2
(Fig. 3B). In ACV-treated mice, peak titers of HSV-2 MS
replication were only ,10 pfu per footpad, which was 1,000-fold
lower than HSV-2 MS titers in untreated mice (Fig. 3B). This
latter observation appeared to explain how 100% of ACV-treated
mice survived HSV-2 MS inoculation of the rear footpad without
any overt signs of disease.
On Day 30, all mice were boosted via injection of the same
immunogens into their left, rear footpads (Fig. 3A). Mice were bled
on Day 60 p.i. and sera were analyzed for the presence of gD-2-
specific antibody. Mice immunized with culture medium (naı ¨ve) or
GFP did not possess detectable levels of gD-2-specific antibody
(Fig. 3C). Mice vaccinated with the gD-2 subunit vaccine possessed
titers of gD-2-antibody that were 2,000-fold above background
(Fig. 3C). Based on the 1:100 dilution of serum used in the ELISA,
gD-2-vaccinated mice had an average gD-2 antibody titer of
1:200,000. Mice vaccinated with HSV-2 0DNLS or MS possessed
far lower levels of gD-2 antibody that were 97- and 85-fold above
background, respectively (Fig. 3C). Thus, the gD-2 subunit vaccine
formulation used in the current study elicited a gD-2 antibody
response similar in potency to that described elsewhere [6,37,38].
Protective immunity elicited by vaccination with HSV-2
0DNLS versus gD-2
On Days 80, 90, and 100 post-immunization, n=5 mice per
group were challenged with 500,000 pfu per vagina of wild-type
HSV-2 (Fig. 3A). The summated results of replicate challenge
experiments are presented, as follows. On Days 1 and 2 post-
challenge, naı ¨ve mice shed an average 200,000 and 50,000 pfu per
vagina, respectively (‘X’ symbols in Figs. 4A, 4B). Immunization
with gD-2 or GFP did not alter the course of HSV-2 vaginal
shedding for the first 5 days post-challenge (Fig. 4A, 4B). In
contrast, immunization with HSV-2 0DNLS or MS reduced
shedding of the HSV-2 challenge virus from the vagina at all times
(Fig. 4A, 4B). On average, 0DNLS- and MS-immunized mice shed
a respective 430- and 120-fold less HSV-2 challenge virus between
Days 1 and 7 relative to naı ¨ve mice (Fig. 4C). In contrast, gD-2
and GFP-immunized mice shed a respective 3.4- and 0.9-fold less
HSV-2 per vagina relative to naı ¨ve mice (Fig. 4C). Thus, mice
immunized with HSV-2 0DNLS shed an average 125-fold less
HSV-2 MS from their vaginas relative to gD-2-immunized mice,
and this difference was significant (p,10
223; two-sided, paired
t-test).
None of the naı ¨ve or GFP-immunized mice survived HSV-2
vaginal challenge, and only 20% of gD-2-immunized mice
survived the same challenge (Fig. 4D). In contrast, 15 of 15
0DNLS-immunized mice and 15 of 15 MS-immunized mice
Figure 2. Mice immunized with HSV-2 0DNLS are resistant to
HSV-2 vaginal challenge. Mice were treated with 2 mg medox-
yprogesterone 7 and 3 days prior to vaginal HSV-2 challenge [54]. On
Day 56 p.i., HSV-2 0DNLS- and MS-immunized mice were challenged
with 500,000 pfu per vagina of HSV-2 MS. (A) HSV-2 shedding from the
vagina between Days 2 and 6 post-challenge in naı ¨ve mice (n=10)
versus mice inoculated in the rear footpads with HSV-2 MS (n=5) or
HSV-2 0DNLS (n=5). (B) HSV-2 shedding from the vagina of naı ¨ve mice
versus mice inoculated in the eyes, nose, or vagina with HSV-2 0DNLS
(n=5 per group). In panels A and B, a single asterisk (*) denotes a
probability, p, ,0.05 and a double asterisk (**) denotes p,0.001 that
HSV-2 shedding was equivalent to naı ¨ve controls on that day, as
determined by one-way ANOVA and Tukey’s post hoc t-test. (C) Survival
frequency of naı ¨ve mice (n=10) versus immunized mice (n=5 per
group) after HSV-2 challenge of the vagina. A double asterisk (**)
denotes p,0.001 that survival frequency was equivalent to naı ¨ve mice.
doi:10.1371/journal.pone.0017748.g002
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MS-immunized mice survived without any overt symptoms of
disease for 30 days after vaginal challenge; however, 1 of 15 mice
in each group exhibited limited perivaginal fur loss between 10
and 30 days after HSV-2 vaginal challenge.
To verify that protective immunity against HSV-2 was not
unique to the vagina, mice were also challenged with 100,000 pfu
per eye of HSV-2 MS on Days 80, 90, and 100 post-vaccination.
In general, equivalent results were obtained in ocular and vaginal
challenge experiments (Figs. 4 and S3). However, fewer mice
survived HSV-2 MS challenge of the eyes because of the
extraordinary rapidity with which HSV-2 MS spreads from the
eyes to the central nervous system (6–7 days to death; Fig. 1A).
Consequently, 0 of 15 mice immunized with culture medium,
GFP, or gD-2 survived HSV-2 MS challenge of the eyes (Fig.
S3D). In contrast, 14 of 15 mice immunized with HSV-2 0DNLS-
or MS survived the same, stringent ocular HSV-2 challenge (Fig.
S3D), and ,90% of these mice survived without any overt
symptoms of disease for 30 days after challenge. However,
histological analysis was not performed on HSV-2 MS-challenged
vaginas or eyes, and we cannot exclude the possibility that HSV-2
MS caused pathological changes in the infected tissues that were
not visible upon gross examination of mice. These results indicated
that mice immunized with HSV-2 0DNLS were significantly better
protected against wild-type HSV-2 challenge than gD-2-immu-
nized mice, which remained vulnerable to wild-type HSV-2
replication and disease.
Re-evaluating the magnitude of the HSV-2-specific IgG
antibody response
Protective immunity against HSV-2 normally involves lympho-
cyte recognition of many HSV-2 proteins [56,57,58,59]. Thus, we
Figure 3. Immunization with HSV-2 0DNLS, gD-2, or control immunogens. (A) Design of vaccine-challenge experiments. Protein-immunized
mice were injected in their right, rear footpads on Day 0 with 10 mg monophosphoryl lipid A, 2.5 mg gD-2 or GFP, and alum (n=40 per group). On
Day 30, mice received an equivalent immunization in their left, rear footpads. Virus-immunized mice received injections on Days 0 and 30 of culture
medium (mock), 1610
6 pfu of HSV-2 0DNLS, or 1610
6 pfu of HSV-2 MS (n=40 per group). Mice immunized with HSV-2 MS received 1 mg/ml
acyclovir in drinking water from Days 21t o+20 p.i. On Day 60, blood was harvested from all mice, and on Days 80, 90, or 100, mice were challenged
with wild-type HSV-2 MS. (B) HSV-2 replication in mouse footpads. In a parallel experiment, mice were footpad-injected with 1610
6 pfu of HSV-2 MS
in the presence or absence of oral acyclovir (ACV) or 1610
6 pfu of HSV-2 0DNLS. On Days 1, 2, and 3 p.i., footpad titers of infectious HSV-2 were
determined in n=8 mice per group; on days 5 and 7 p.i., footpad titers were determined in n=4 mice per group. All datum points represent mean 6
sem pfu per footpad. A double asterisk (**) denotes p,0.001 that viral titers per footpad were the same as HSV-2 MS-inoculated mice not treated
with acyclovir. (C) Mean 6 sem relative abundance of gD-2 specific IgG antibody in mouse serum on Day 60 p.i., as determined by ELISA on 1:100
dilutions of mouse serum (n=30 per group). Relative units of IgG abundance are expressed as ‘‘fold-increase above background,’’ as determined
relative to a 0.33-log dilution series of high titer anti-HSV-2 antiserum that provided the standard curve that defined the quantitative relationship
between anti-gD-2 IgG antibody abundance and colorimetric development. A double asterisk (**) denotes p,0.001 that gD-2-antibody levels were
equivalent to naı ¨ve (medium-treated) mice, as determined by one-way ANOVA and Tukey’s post hoc t-test.
doi:10.1371/journal.pone.0017748.g003
Live vs Dubunit HSV-2 Vaccine
PLoS ONE | www.plosone.org 5 March 2011 | Volume 6 | Issue 3 | e17748suspected that the gD-2 antibody-capture ELISA (Fig. 3C) was not
representative of the magnitude of the polyclonal antibody response
elicited by HSV-2 0DNLS or MS. To test this hypothesis, Day 60
serum samples collected from mice prior to HSV-2 challenge were
re-analyzed in assays better suited to estimate the magnitude of a
polyclonal antibody response against multiple HSV-2 antigens;
namely, 1. antibody-dependent neutralization of HSV-2 virions
(which contain at least 6 glycoproteins; [43,60]) and 2. antibody-
binding to HSV-2-infected Vero cells.
Antisera from naı ¨ve- and GFP-immunized mice consistently
failed to neutralize the infectivity of ,175 pfu of HSV-2 at a
serum dilution of 1:46 (Fig. 5A). Antisera from gD-2-immunized
mice had an average neutralizing antibody titer of 70 (Fig. 5A).
Antisera from 0DNLS- or MS-immunized mice was ,10-fold
more potent in its capacity to neutralize infectious HSV-2.
Specifically, antisera from mice immunized with HSV-2 0DNLS
or MS had an average neutralizing antibody titer of ,950
(Fig. 5A).
Figure 4. Resistance of naı ¨ve versus immunized mice to vaginal HSV-2 infection. Mice were treated with 2 mg medoxyprogesterone 7 and
3 days prior to vaginal HSV-2 challenge [54]. On Days 80, 90, or 100 p.i., mice were challenged with 500,000 pfu per vagina of HSV-2 MS (n=5 per
group). The summated results from all three experiments are presented in each panel (gn=15 per group). (A) Vaginal HSV-2 shedding between Days
1 and 7 post-challenge in mice that were naı ¨ve or immunized with gD-21-306t versus HSV-2 0DNLS. (B) Vaginal HSV-2 shedding in mice that were naı ¨ve
or immunized with GFP versus HSV-2 MS. In panels A and B, a single asterisk (*) denotes p,0.05 and a double asterisk (**) denotes p,0.001 that HSV-
2 shedding was equivalent to naı ¨ve mice on that day, as determined by one-way ANOVA and Tukey’s post hoc t-test. (C) Mean 6 sem reduction in
HSV-2 shedding on Days 1–7 post-challenge relative to the average titer of HSV-2 shed by naı ¨ve mice on that day (n=75 per group). In panel C, a
single asterisk (*) denotes p,0.05 and a double asterisk (**) denotes p,0.001 that reductions in vaginal shedding of HSV-2 MS were significantly
greater than a value of 1, as determined by one-way ANOVA and Tukey’s post hoc t-test. The difference in reductions in HSV-2 MS vaginal shedding
between 0DNLS- and gD-2-immunized mice was significant (p,10
223; two-sided, paired t-test). (D) Survival frequency over time following HSV-2 MS
challenge of the vagina. A double asterisk (**) denotes p,0.001 that survival frequency was equivalent to naı ¨ve mice, as determined by Fisher’s Exact
Test. The survival rate of gD-2 immunized mice was not significantly different than naı ¨ve mice (p=0.22, Fisher’s Exact Test).
doi:10.1371/journal.pone.0017748.g004
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polyclonal antibody reactivity against the many HSV-2 proteins
present in virus-infected cells. In the first assay, fixed and
permeabilized HSV-2 plaques were incubated with 1:5,000
dilutions of mouse serum, and stained with Alexa Fluor-594-
conjugated secondary antibody. When fixed monolayers contain-
ing HSV-2 plaques were incubated with GFP-antiserum, binding
of IgG to HSV-2 infected cells was not observed (Fig. 5B). Antisera
from gD-2-immunized mice contained IgG that bound HSV-2
plaques, but the immunofluorescent signal was weak (Fig. 5B). In
contrast, antisera from 0DNLS- or MS-immunized mice contained
IgG that bound HSV-2-infected cells to much higher levels than
surrounding, uninfected Vero cells (Fig. 5B).
Binding of IgG antibody to HSV-2-infected cells was quantified
by a flow cytometry-based assay, which is summarized in Fig. S4.
As expected, IgG antibodies in naı ¨ve serum and GFP-antiserum
did not preferentially bind HSV-2-infected Vero cells versus
uninfected Vero cells (Fig. 5C). Serum samples from gD-2-
immunized mice contained IgG antibodies that bound HSV-2-
infected cells to levels that were an average 15-fold greater than
the background rate of antibody adhesion to uninfected cells
(Fig. 5C). Serum from 0DNLS- or MS-immunized mice contained
Figure 5. Polyclonal HSV-2 IgG antibody response elicited by HSV-2 0DNLS, gD-2, or control immunogens. (A) Mean 6 sem
neutralizing antibody titer of Day 60 serum samples (n=20 per group). The titer of each serum sample was considered to be the reciprocal of the
largest serum dilution that reduced HSV-2’s cytopathic effect in Vero cell monolayers by at least 50%. (B) Representative immunofluorescent labeling
of fixed HSV-2 plaques with a 1:5,000 dilution of Day 60 serum from each immunization group. (C) Flow cytometric measurement of pan-HSV-2-
specific IgG levels in Day 60 sera, as determined by IgG binding to fixed HSV-2-infected cells versus uninfected Vero cells (n=8 per group). In panels A
and C, a double asterisk (**) denotes p,0.001 that neutralizing antibody titers or pan-HSV-2 IgG levels were equivalent to naı ¨ve mice, as determined
by one-way ANOVA and Tukey’s post hoc t-test. The difference in pan HSV-2 IgG levels between 0DNLS- and gD-2-immunized mice was significant
(p,0.0001; two-sided, paired t-test). (D) Regression analysis of the logarithm of pan-HSV-2 IgG levels (x-variable, as measured on Day 60) in n=25
mice versus the logarithmic reduction in vaginal HSV-2 MS shedding (y-variable, as measured on Day 81) observed in the same n=25 mice at
24 hours post-vaginal challenge. The x-variable data is based on a subset of the data summarized in Figure 5C, and likewise the y-variable data is
based on a subset of the data summarized in Figure 4C. The individual datum points are derived from n=5 mice per group that were immunized
with medium (naı ¨ve), GFP, gD-2, HSV-2 0DNLS, or HSV-2 MS (ACV-restrained infection), as indicated in the legend in Panel D. The quantity on the y-
axis, Dlog (pfu/vagina), represents the logarithmic decrease of HSV-2 MS shed from an individual mouse vagina at 24 hours post-challenge relative to
5.20 logs, which was the average titer of HSV-2 MS shed by naı ¨ve mice at 24 hours post-challenge. The goodness-of-fit of the correlation between log
(pan-HSV-2 IgG) and Dlog (pfu/vagina) was r
2=0.83 and the slope of the correlation was 1.3860.13 (p,10
29).
doi:10.1371/journal.pone.0017748.g005
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antigen. Specifically, 0DNLS antiserum contained pan-HSV-2
IgG levels that were an average 190-fold above background
(Fig. 5C), and which were significantly greater than observed in
gD-2-immunized mice (p,0.0001; two-sided, paired t-test).
The average pan-HSV-2 IgG level in each treatment group
(Fig. 5C) appeared to correlate with reductions in vaginal HSV-2
MS shedding (Fig. 4C). To test the validity of this inference,
regression analysis was applied to a data set collected from n=25
mice (n=5 per immunization group) included in both assays.
Specifically, regression analysis was used to determine if log (pan-
HSV-2 IgG level) in an individual mouse was predictive of log
(reduction in HSV-2 MS shedding) observed in the same mouse
24 hours after vaginal challenge (Fig. 5D). Each mouse was
challenged with HSV-2 MS on Day 80, and the reduction in
HSV-2 MS vaginal shedding from an individual mouse was
calculated as y=Dlog (pfu/vagina)=5.20 log10 pfu/vagina (mean
naı ¨ve titer) – HSV-2 titer shed from this mouse (Fig. 5D). Mice
immunized with HSV-2 0DNLS or MS possessed the highest
levels of pan-HSV-2 IgG (x-variable) and exhibited the largest
reductions in HSV-2 MS vaginal shedding at 24 hours post-
challenge (y-variable; Fig. 5D). Mice immunized with gD-2
possessed modest levels of pan-HSV-2 IgG and likewise exhibited
modest reductions in HSV-2 MS vaginal shedding (Fig. 5D).
Regression analysis confirmed that log (pan-HSV-2 IgG) in mice
was predictive of the logarithmic reduction in HSV-2 MS vaginal
shedding (Fig. 5D; r
2=0.83, p,10
29 that x- and y-variables were
unrelated). These data indicated that 1. immunization with HSV-
20 DNLS elicited a greater pan-HSV-2 IgG antibody response
than a gD-2 subunit vaccine (Fig. 5C; p,0.0001; two-sided, paired
t-test), and 2. pan-HSV-2 IgG antibody levels were highly
predictive of protection against HSV-2 MS vaginal challenge
(Fig. 5D).
In vivo imaging of vaccine-induced protection: tests with
HSV-2 MS-luciferase
Individuals who carry latent HSV infections are resistant to
superinfection with the same HSV serotype [61,62,63]. Likewise,
mice immunized with HSV-2 0DNLS or MS might be resistant to
superinfectionwithwild-typeHSV-2(Fig.4).Totestthishypothesis,
HSV-2 challenge viruses were constructed whose spread could be
imaged in vivo. Specifically, HSV-2 MS-luciferase and HSV-2 MS-
GFP were constructed by inserting a luciferase or GFP expression
cassette into HSV-2’s non-essential LAT locus (Fig. S5).HSV-2 MS-
luciferase spread was compared in immunized mice (Fig. 6), and the
results are summarized as follows.
On Day 130 post-immunization, naı ¨ve or immunized mice were
challenged with 500,000 pfu per vagina of HSV-2 MS-luciferase
(n=2 per group), and bioluminescent imaging was used to
visualize viral spread (Fig. 6A). The spread of HSV-2 MS-
luciferase from the vaginas of naı ¨ve and gD-2-immunized mice
was readily visualized between Days 2 and 6 post-challenge
(Fig. 6A). In contrast, luciferase expression was not detectable in
0DNLS- or MS-immunized mice (Fig. 6A). A replicate challenge
experiment performed on Day 50 p.i. yielded equivalent results
(n=3 mice per group). The summated results were statistically
analyzed, and the primary conclusions are presented (Fig. 6B). In
HSV-2 MS-luciferase-challenged naı ¨ve mice, luciferase activity
was an average 14-, 90-, and 270-fold above background on Days
2, 4, and 6 post-challenge, respectively (Fig. 6B). In gD-2-
immunized mice, luciferase activity was reduced by 4.5- and 20-
fold on Days 4 and 6 relative to naı ¨ve controls, respectively, but
was still significantly above background (Fig. 6B). In contrast,
luciferase activity in 0DNLS- or MS-immunized mice did not
significantly differ from uninfected control mice injected with
luciferin substrate (not shown) on Days 2, 4, or 6 post-challenge
(Fig. 6B). Between Days 2 and 6 post-vaginal challenge, luciferase
activity was an average 10-fold lower in 0DNLS- versus gD-2-
immunized mice and this difference was significant (p,0.0001;
two-sided, paired t-test).
HSV-2 MS-luciferase replication and spread may have
occurred inside the vagina of 0DNLS- or MS-immunized mice at
levels that were not detected by our bioluminescent imager. To
address this caveat, an ocular challenge experiment was performed
on Day 130 post-immunization such that an external surface
served as the site of challenge (n=2 mice per group). Following
inoculation with 100,000 pfu per eye of HSV-2 MS-luciferase,
luciferase activity was significantly greater than background in the
eyes and faces of naı ¨ve and gD-2-immunized mice between Days 2
and 6 post-challenge (Fig. 6C, 6D). In contrast, luciferase activity
was not detectable in mice immunized with HSV-2 0DNLS or MS
(Fig. 6C, 6D). A replicate challenge experiment performed on Day
50 p.i. yielded equivalent results (n=2 mice per group). The
summated results were statistically analyzed, and the primary
conclusions are presented (Fig. 6D). In HSV-2 MS-luciferase-
infected naı ¨ve mice, luciferase activity in the eyes and faces of mice
was an average 15-, 580-, and 150-times background on Days 2, 4,
and 6 post-challenge, respectively (Fig. 6D). In gD-2-immunized
mice, luciferase activity was reduced relative to naı ¨ve mice by 7-
and 3-fold on Days 4 and 6 post-challenge, respectively (Fig. 6D).
Between Days 2 and 6 post-ocular challenge, luciferase activity
was an average 25-fold lower in 0DNLS-versus gD-2-immunized
mice and this difference was significant (p,0.0001; two-sided,
paired t-test). Therefore, mice immunized with HSV-2 0DNLS
were 10- to 25-fold more resistant to HSV-2 MS-luciferase
challenge than gD-2-immunized mice.
In vivo imaging of vaccine-induced protection: tests with
HSV-2 MS-GFP
Bioluminescent imaging of luciferase activity in vivo is a
macroscopic measurement. We reasoned that HSV-2 MS-
luciferase might reproducibly establish microfoci of infection in
0DNLS- and MS-immunized mice that were not detectable with a
bioluminescent imager. To address this possibility, naı ¨ve and
0DNLS-immunized mice were challenged with 100,000 pfu per
eye of HSV-2 MS-GFP. At 24 hours post-challenge, GFP
expression was imaged in mouse eyes and faces using an inverted
fluorescent microscope (n=3 per group). As predicted, foci of
HSV-2 MS-GFP replication were consistently detected in the eyes
of both naı ¨ve and 0DNLS-immunized mice at 24 hours post-
challenge (Fig. 7). However, the extent of HSV-2 MS-GFP spread
in the eyes (i.e., area of GFP expression) was restricted by an order
of magnitude in 0DNLS-immunized mice relative to naı ¨ve controls
(Fig. 7). Thus, 0DNLS-vaccine-induced protection against HSV-2
infection appeared to be active within just the first 24 hours post-
challenge (Fig. 7). Consistent with this interpretation, HSV-2 MS-
GFP consistently caused a zosteriform pattern of spread in naı ¨ve
mice (Fig. S6), and fatal encephalitis developed within 8 days post-
challenge. In contrast, sites of HSV-2 MS-GFP replication were
not visible in the eyes or facial epithelium of 0DNLS-immunized
mice at any time beyond Day 1 post-challenge (Fig. S6).
Therefore, in vivo imaging indicated that 0DNLS-immunized mice
were able to rapidly control the spread of a superinfecting HSV-2
virus (Fig. 6, 7, and S6).
Summary of HSV-2 MS challenge experiments
In the current study, several hundred female ICR mice were
challenged with the MS strain of wild-type HSV-2 in nineteen
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of these tests are summarized, as follows. None of the naı ¨ve mice
used in these tests survived HSV-2 MS challenge of the eyes (0 of
99) or vagina (0 of 25). None of the GFP-immunized mice survived
HSV-2 MS challenge of the eyes (0 of 15) or vagina (0 of 15). None
of the gD-2-immunized mice survived HSV-2 MS challenge of the
eyes (0 of 30), but 3 of 15 survived HSV-2 MS challenge of the
vagina (Table 1). Mice immunized with live HSV-2 viruses were
far better protected against later exposures to wild-type HSV-2
MS. Specifically, 79 of 80 0DNLS-immunized mice survived
HSV-2 MS challenge of the eyes, and 35 of 35 0DNLS-immunized
mice survived HSV-2 MS challenge of the vagina (Table 1). Thus,
0DNLS-immunized mice were ,15 times more likely to survive
HSV-2 MS challenge than gD-2-immunized mice, and this
difference was significant (Table 1; p,10
28, Fisher’s Exact Test).
Likewise, 46 of 49 MS-immunized mice survived HSV-2 MS
challenge of the eyes, and 15 of 15 MS-immunized mice survived
HSV-2 MS challenge of the vagina (Table 1).
Based on the results of individual challenge experiments (Table
S1), we compared the survival rates of gD-2 and 0DNLS-
immunized mice as a function of time between immunization
and HSV-2 MS challenge (Fig. 8). In a total of 8 experiments,
Figure 6. Vaccine-induced protection against HSV-2 MS-luciferase infection. (A and C) Mice were treated with 2 mg medoxyprogesterone
7 and 3 days prior to vaginal HSV-2 challenge [54]. On Day 130 p.i., mice were challenged with (A) 500,000 pfu per vagina or (C) 100,000 pfu per eye
of HSV-2 MS-luciferase, and were anaesthetized and injected with 3 mg D-luciferin substrate at times post-challenge for imaging in a bioluminescent
imager. Not shown in panels A or C are the age- and sex-matched, uninfected control mice included in these analyses that were anaesthetized and
injected with 3 mg D-luciferin substrate at the same time, and which served as a background control to define the background level of light emission
recorded from each mouse by the bioluminescent imager. (B and D) Mean 6 sem of luciferase activity in mice challenged in the (B) vagina or (D)
eyes with HSV-2 MS-luciferase, as measured by the fold-increase in light emission from each mouse relative to an uninfected background control
mouse injected with 3 mg D-luciferin substrate. In the vaginally challenged group, each datum point represents the mean 6 sem of luciferase activity
based on gn=5 per group (n=3 challenged on Day 50 p.i. and n=2 challenged on Day 130 p.i.). In the ocularly challenged group, each datum point
represents the mean 6 sem of luciferase activity based on gn=4 per group (n=2 challenged on Day 50 p.i. and n=2 challenged on Day 130 p.i.). A
single asterisk (*) denotes p,0.05 and a double asterisk (**) denotes p,0.001 that luciferase activity in HSV-2 MS-luciferase-challenged mice was
significantly different from uninfected control mice injected with 3 mg D-luciferin, as determined by one-way ANOVA and Tukey’s post hoc t-test. In
both vaginal and ocular challenge tests, luciferase activity was significantly different between gD-2- and 0DNLS-immunized mice (p,0.0001; two-
sided, paired t-test).
doi:10.1371/journal.pone.0017748.g006
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PLoS ONE | www.plosone.org 9 March 2011 | Volume 6 | Issue 3 | e17748Figure 7. HSV-2 MS-GFP infection is established in the eyes of HSV-2 0DNLS-immunized mice, but is rapidly restricted. A naı ¨ve and
HSV-2 0DNLS-immunized mouse, as observed 24 hours after challenge with 100,000 pfu per eye of HSV-2 MS-GFP. Experiments were performed on
n=3 mice per group and a representative animal is shown. The complete progression of HSV-2 MS-GFP infection in this naı ¨ve mouse versus
immunized mouse is shown in Figure S6.
doi:10.1371/journal.pone.0017748.g007
Table 1. Survival rates in HSV-2 MS challenge experiments.
HSV-2 MS challenge of the eye (100,000 pfu/eye)
naı ¨ve















HSV-2 MS challenge of the vagina (500,000 pfu/vagina)



























aImmunization status of mice at the time of HSV-2 MS challenge, which were vaccinated 45 to 190 days earlier with culture medium (naı ¨ve), GFP, gD-2, 0DNLS, or HSV-2
MS.
bFrequency of mice that survived until 30 days after challenge with wild-type HSV-2 MS. The total number of independent experiments performed is indicated by the n-
value in parentheses.
*p,0.05 that the survival frequency was equivalent to naı ¨ve mice following HSV-2 MS challenge, as determined by Fisher’s Exact Test.
**p,10
26 that survival frequency was equivalent to naı ¨ve mice following HSV-2 MS challenge, as determined by Fisher’s Exact Test.
{p,10
28 that survival frequency was equivalent between mice immunized with HSV-2 0DNLS versus a gD-2 subunit vaccine following HSV-2 MS challenge, as
determined by Fisher’s Exact Test.
doi:10.1371/journal.pone.0017748.t001
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(Fig. 8, Table S1). In a total of 15 experiments, 9961% of 0DNLS-
immunized mice survived HSV-2 MS challenge (Fig. 8, Table S1).
This difference in survival frequency between 0DNLS- and gD-2-
immunized mice was significant (p,10
215; two-sided Student’s t-
test). At all times post-immunization, gD-2 immunized mice were
incompletely protected against HSV-2 MS (Fig. 8). In contrast,
nearly 100% of 0DNLS-immunized mice survived HSV-2 MS
challenge regardless of whether they were challenged on Days 56,
80, 100, or 190 post-immunization (Fig. 8). We conclude that mice
immunized with a live viral vaccine, HSV-2 0DNLS, possessed
significantly greater protection against lethal HSV-2 challenge
than mice immunized with a gD-2 subunit vaccine.
Discussion
Measuring vaccine-induced resistance to HSV-2
HSV-2 vaccines are often described in the binary terms of
effective versus ineffective. Such qualitative terms and qualitative
measures of protection (e.g., reductions in disease and death)
provide only a crude basis for estimating the potency of HSV-2
vaccine candidates. The quantity of vaccine-induced resistance to HSV-
2 is a function of the frequency of HSV-2 specific B and T cells
that have encountered their cognate antigen, and as a result have
proliferated and/or differentiated into memory or effector cells.
The adaptive immune response to any antigen involves thousands
to millions of lymphocytes, and thus behaves as a continuous
variable that varies over at least 2 to 3 orders of magnitude. If
adaptive immunity to HSV-2 behaves as a continuous variable in
nature, then the potency of vaccine-induced resistance to HSV-2 is best
described in similarly quantitative terms.
Such theoretical considerations have little value unless a method
exists to measure the proposed quantity of vaccine-induced resistance to
HSV-2. Herein, we identify four measures that strongly correlate
with functional resistance to HSV-2; namely, 1. quantitative
reductions in shedding of HSV-2 challenge virus from the vagina
(Fig. 4C); 2. abundance of IgG antibody against total HSV-2
antigen (Fig. 5C); 3. in vivo imaging and quantitation of restricted
spread of a bioluminescent HSV-2 challenge virus from the site of
challenge (Fig. 6); and 4. in vivo imaging of restricted spread of a
GFP-expressing HSV-2 challenge virus at the site of challenge
(Fig. 7). The last three of these methods are novel. We propose that
such measures of vaccine-induced resistance to HSV-2 provide a
superior basis for analyzing HSV-2 vaccine potency, as opposed to
more qualitative measures of vaccine-induced protection, such as
i. reduced disease score or ii. increased survival.
Resistance to HSV-2 elicited by a gD-2 subunit versus
0DNLS virus
Mice immunized with a gD-2 vaccine exhibited significant
resistance to HSV-2 relative to naı ¨ve mice, as demonstrated by i. a
3.4-fold reduction in HSV-2 challenge virus shedding from the
vagina (Fig. 4C); ii. a 15-fold increase in pan-HSV-2 IgG levels
(Fig. 5C); and iii. a 5- to 20-fold reduction in the spread of a
bioluminescent HSV-2 challenge virus (Fig. 6).
These results are consistent with published findings that a gD-2
vaccine elicits significant resistance to HSV-2 infection
[6,37,38,42]. However, the magnitude of gD-2 vaccine-induced
resistance (3- to 20-fold) was dwarfed by the HSV-2 0DNLS
vaccine, which elicited a 200- to 500-fold increase in resistance to
HSV-2 infection (Fig. 4, 5, 6). Such a reference point is absent
from most gD-2 vaccine-challenge studies, which focus on the
difference between naı ¨ve and gD-2-immunized animals
[6,37,38,42]. A recent study reported that naı ¨ve guinea pigs and
guinea pigs vaccinated with gD-2, alum, and MPL shed equivalent
levels of HSV-2 challenge virus from their vaginas on Days 1, 2,
and 4 post-challenge, (Fig. 1C of Ref. [6]). This is comparable to
what we observed in mice (Fig. 4A). Thus, we concur with the
prevailing view that gD-2 subunit vaccines elicit significant
resistance to HSV-2 infection. However, we note that a live
HSV-2 ICP0
2 virus, 0DNLS, elicits 10 to 100 times greater
protection against genital herpes.
One caveat of the current study is that tests were performed in
mice, and not the preferred guinea pig HSV-2 vaccine-challenge
model. Studies are in progress to determine if HSV-2 0DNLS will
be equally effective as a HSV-2 vaccine in guinea pigs. A second
caveat of the study is that we did not use Glaxo Smith Kline’s
proprietary AS04 adjuvant system [38]. Thus, our gD-2 vaccine
formulation may not elicit the same level of resistance to HSV-2
that may be obtained with a more potent combination of gD-2 and
adjuvant [6,38].
Why does the 0DNLS vaccine elicit greater protection
against HSV-2 infection?
Prior to the recent Simpilirix
TM vaccine trials, two earlier
permutations of a gD-2 subunit yielded equivocal results in human
clinical trials [36,41]. Based on the premise that a more potent
adjuvant (alum+MPL) would increase gD-2’s efficacy as a genital
herpes vaccine [37,38], the NIAID invested $27.6 million in the
Herpevac/Simpilirix
TM vaccine trial for women conducted
Figure 8. HSV-2 0DNLS-induced protective immunity does not
decline between Days 30 and 190 post-immunization. The mean
6 sem frequency of survival following HSV-2 MS challenge was
compared over time in mice immunized with HSV-2 0DNLS or gD-2. The
gD-2 plot is based on survival frequencies observed in challenge
experiments performed between Days 30–60 (n=1), 70–80 (n=3), and
90–100 (n=4) post-immunization. The 0DNLS plot is based on survival
frequencies observed in challenge experiments performed between
Days 30–60 (n=5), 70–80 (n=4), 90–100 (n=4), and 140–190 (n=2)
post-immunization. Specific outcomes of the n=15 challenge experi-
ments are summarized in Table S1. The double asterisk (**) denotes that
differences in percent survival of 0DNLS-versus gD-2-immunized mice
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published, Glaxo Smith Kline recently announced that this latest
gD-2 subunit vaccine did not reduce the rate at which women
acquired HSV-2 genital herpes [49].
After investing so much time and effort into gD-2 subunit
vaccines [33], there is ample cause for dismay at the failure of a
promising genital herpes vaccine [48]. However, we would suggest
that the relevant question moving forward is this: ‘‘Is it reasonable to
expect that an immune response elicited against a single HSV-2 protein should
render the body completely resistant to infection with an actual HSV-2 virus?’’
Viruses are highly evolved genetic elements whose complexity
exceeds the sum of their proteins. As a result, the polyclonal
immune response to HSV-2 is more complex than the immune
response to a model antigen (i.e., HSV?OVA) (reviewed in Ref.
[50,64]). For the immunologist, we offer three reasons that a gD-2
subunit vaccine might be ineffective as a genital herpes vaccine
[48]. First, it is unlikely that the adaptive immune response to
HSV-2 hinges upon lymphocytes that recognize a single HSV-2
protein. Second, the T-cell response to HSV-2 involves, at a
minimum, CD8
+ T cells specific for the viral proteins ICP0, ICP4,
ICP6, virion protein 5, and virion components encoded by the
UL25, UL46, UL47, and UL49 genes [56,57]. Third, we present
evidence that the B-cell response to HSV-2 cannot be directed
solely against gD-2 (Fig. 3C vs 5C); a subsequent study will address
the fact that 0DNLS-immunized mice possess serum antibodies
against .15 HSV-2 proteins (unpublished data of W. Halford).
While it is reasonable to assume that HSV-2 0DNLS elicits a
broader T cell response against HSV-2 than a gD-2 subunit
vaccine, further investigation will be required to test this
hypothesis.
For the non-immunologist, we offer the following analogy to
illustrate why we question the validity of the assumption that a gD-
2 subunit vaccine should be sufficient to prevent genital herpes
[33,48]. In human terms, relying on a gD-2 subunit vaccine to
prevent genital herpes is like trying to capture a criminal (HSV-2)
in a city (the body) by releasing a photograph of the criminal’s nose
(one subunit). While the nose may be a distinguishing feature, a full
portrait of the criminal would generate a larger population of
informants (antibodies and T-cells) better able to guide police
(leukocytes) to the criminal’s location. Immunologists will not
require this analogy to appreciate that a live HSV-2 virus possesses
far more epitopes than a HSV-2 subunit vaccine. However, most
viral vaccines continue to be based upon subunit vaccines that
contain ,10% of the epitopes encoded by a virus. Perhaps it is
time that immunological breadth should play a larger role in
vaccine design, as vaccines that contain .25% of a pathogen’s
proteins would be more likely to confer useful protection against a
pathogen.
Two decades ago, it appeared that gD-2 subunit vaccines would
be sufficient to prevent genital herpes in the human population
[33]. Today, the available evidence raises questions about the
viability of gD-2 subunits or any strategy that proposes to elicit
100% protection against HSV-2 by immunizing with 1% of HSV-
2’s proteome [11,12,13,14,15,16,17,18,19]. We propose that the
methods described herein for quantifying and visualizing vaccine-
induced resistance to HSV-2 (Fig. 4, 5, 6, 7) should prove useful in the
future for determining if any subunit vaccine is as effective as a
live-attenuated HSV-2 virus, such as 0DNLS.
Live, replicating viruses: our most successful mode of
vaccinating against viral disease
Originally, the term ‘vaccination’ meant to inoculate a person
with a less virulent virus (vaccinia virus) to elicit a cross-protective
immune response against the smallpox virus [65,66]. When we
have emulated the original approach, and used replication-
competent viruses as the immunogen, we have succeeded in
preventing yellow fever, poliomyelitis, mumps, measles, rubella,
chickenpox, and shingles [67,68,69,70,71,72]. In the past 30 years,
research into live-attenuated viral vaccines has been largely
replaced with research into viral subunit vaccines.
The term subunit ‘vaccine’ implies that the use of a viral
protein, in lieu of a live virus, is a minor modification of the
original strategy. However, we are unaware of any studies that
validate this assumption. To the best of our knowledge, this is the
first study in which immunization with (1) a viral protein subunit
was compared in side-by-side fashion to (2) a live-attenuated
variant of the same virus. In this study, immunization with a gD-2
subunit vaccine elicited 1–10% of the resistance to HSV-2 that
was attainable with a live virus. We will be interested to learn if this
observation is unique to HSV-2 or applies to other viruses. In
principle, one means to test this hypothesis would be to compare
the efficacy of immunization with one of the live viruses used in
childhood vaccines (i.e., varicella-zoster virus [VZV] Oka strain
[68], measles virus Schwarz strain [69], mumps virus Jeryl Linn
strain [70], or rubella virus Cendehill strain [71]) relative to
immunization with a protein subunit derived from the same virus.
An important question that remains to be addressed is whether
or not viral replication is essential for HSV-2 0DNLS to elicit
potent and sustained resistance to HSV-2 (Fig. 8). Hence, studies
are in progress to compare the efficacy of the HSV-2 0DNLS
vaccine strain relative to a replication-defective HSV-2 virus,
similar in principle to Sanofi Pasteur’s lead HSV-2 vaccine
candidate, ACAM-529 [23,24,25]. We conclude by noting that
while live viruses, such as HSV-2 0DNLS, are the basis of ,75%
of our effective viral vaccines [67,68,69,70,71,72], there is not a
single vaccine in clinical use that contains a replication-defective
virus.
The relative risk of live-attenuated viral vaccines
Vaccines based on recombinant proteins are safe, but have been
ineffective against herpes and AIDS [73,74]. The cost of subunit
vaccines that rarely succeed is staggering. Each year that herpes
and AIDS vaccines fail means that a. another 20 million people
will be newly infected with HSV-2; b. another 2 million people
will be newly infected with human immunodeficiency virus (HIV);
and c. public faith in vaccines will continue to erode. The original
‘vaccination’ approach [75], in which a weakened virus served as
the immunogen, underlies most of our successes in preventing viral
disease. Perhaps it is time to reconsider the relative risk of the
approach.
Live viral vaccines have always posed a risk to human health.
However, history suggests that the low risk of a well-designed, live-
attenuated viral vaccine is many thousands of times preferable to
the certainty of disease and/or death that occurs when a viral
pathogen is allowed to circulate in the human population. All of
the live-attenuated viral vaccines developed in the 20
th century,
which remain in clinical use worldwide, are generally well
tolerated and highly effective in preventing viral disease
[76,77,78,79].
Mutagenesis of key viral activators, such as ICP0 [80,81,82,83],
is a general strategy that may be used to obtain live-replicating
viruses that are avirulent, but which retain the capacity to present
the entire protein signature of a viral pathogen to the adaptive
immune system [50,52]. The live viral vaccines used in clinical
practice today were developed between 1940 and 1975
[67,68,69,70,71,72], and rely on single-nucleotide substitutions
for their attenuated phenotype [84,85]. We propose that genetic
engineering could be applied to derive a 2
nd generation of live-
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(more stable) due to large, in-frame deletions that are unable to
spontaneously revert to the wild-type genetic code.
Conclusion
Because a-herpesviruses establish life-long infections in neurons,
it has been suggested that a live a-herpesvirus vaccine would be
too dangerous for use in humans [23]. Such claims contradict the
fact that .55 million people have been inoculated with the
varicella-zoster virus (VZV) Oka strain, which like HSV-2 is a
neurotropic herpesvirus [77]. While the VZV Oka strain may
establish latent infections in human neurons and reactivate from
the latent state [86], clinical experience suggests that the risks
associated with this live VZV vaccine are far outweighed by the
benefits of not leaving a population susceptible to the .90% risk of
being infected with wild-type VZV [87]. If clinical experience with
the VZV Oka strain is any indication, then the risks associated
with a live HSV-2 0DNLS vaccine would be preferable to the
current situation in which wild-type HSV-2 is carried by ,1
billion people, and ,20 million people are newly infected each
year with wild-type, disease-causing strains of HSV-2.
It remains to be determined if HSV-2 ICP0
2 mutant viruses,
such as HSV-2 0DNLS, establish latent infections in vaccine
recipients. Likewise, many questions remain about this novel class
of live, interferon-sensitive HSV-2 vaccine [52]. However, what is
clear is that mice immunized with HSV-2 0DNLS were 10- to 100-
fold better protected against genital herpes than mice immunized
with a gD-2 subunit vaccine. Therefore, we conclude that a HSV-
2 vaccine would be more likely to prevent genital herpes if it
contained a live- and appropriately-attenuated HSV-2 virus rather
than another iteration of HSV-2 protein and adjuvant.
Materials and Methods
Ethics Statement
Mice were handled in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. This
study was approved by the Southern Illinois University School of
Medicine Laboratory Animal Care and Use Committee in August
2008, and was assigned Protocol Number #205-08-019. These
protocols remain active and are associated with a grant for the
‘‘Development of an Effective Genital Herpes Vaccine’’ (R21
AI081072).
Cells and viruses
Vero cells and U2OS cells were obtained from the American
Type Culture Collection (Manassas, VA), and High Five
TM insect
cells were obtained from Invitrogen Corporation (Carlsbad, CA).
The ICP0-complementing L7 cell line [88] was kindly provided
by Neal Deluca (University of Pittsburgh). Cell lines were
propagated in Dulbecco’s Modified Eagle’s medium supplement-
ed with 5% fetal bovine serum and antibiotics. The HSV-2
recombinant viruses used in this study (HSV-2 0DNLS, MS-GFP,
and MS-luciferase) were derivative of HSV-2 MS (American
Type Culture Collection). HSV-2 viruses were propagated in
U2OS cells at 34uC following inoculation with a multiplicity of
infection of 0.01 pfu per cell. For both wild-type HSV-2 and
HSV-2 ICP0
2 mutant viruses, viral stocks were generated that
were concentrated 10-fold by ultracentrifugation to achieve a
minimum titer of 3610
7 pfu/ml. An HSV-2 glycoprotein D-
expressing baculovirus was used to purify the gD-2306t protein
[34], and was generously provided by Dr. Gary Cohen and Dr.
Roslyn Eisenberg (University of Pennsylvania). The detailed
methods used to construct and characterize HSV-2 recombinant
viruses used in this study are provided in a recent publication
[52].
Footpad immunization of mice
Female ICR mice were obtained from Harlan Sprague Dawley
(Indianapolis, IN), and were first immunized at 6- to 10-weeks of
age. Prior to immunization, mice were anesthetized by i.p.
administration of xylazine (7 mg/kg) and ketamine (100 mg/kg).
i. Protein subunit vaccines. GFP or gD-2306t protein were
purified from baculovirus vector-infected insect cells as described
below. Protein subunit vaccines were prepared by combining
purified gD-2 or GFP with an equal volume of Imject alum
adjuvant (Thermo Scientific, Rockford, IL) to achieve a protein
concentration of 50 ng per ml. Monophosphoryl lipid A (Avanti
Polar Biolipids, Alabaster, AL) was added to a concentration of
200 ng per ml. After 1 hour, mice were injected in right, rear
footpads with 50 ml of this formulation on Day 0 such that mice
were immunized with 2.5 mg of gD-2 or GFP and 10 mgo f
monophosphoryl lipid A. These doses of gD-2 were modeled after
the gD-2 vaccine-challenge studies of Bourne, et al. (2003, 2005)
[37,38]. Mice received an equivalent injection in left, rear footpads
on Day 30.
ii. HSV-2 viral vaccines. Virus-immunized mice were
treated on Days 0 and 30 as described above, but were
immunized with 50 ml of culture medium containing nothing
(mock), 1610
6 pfu of HSV-2 0DNLS, or 1610
6 pfu of HSV-2
MS. At the time of the first immunzaiton, mice immunized with
HSV-2 MS received 1 mg per ml acyclovir in their drinking water
from Days 21t o+20 p.i. to limit the pathogenesis of the primary
infection.
Inoculation of mice with HSV-2 in the eyes, nostrils, or
vagina
Female ICR mice that received a vaginal inoculum of HSV-2
were pre-treated 7 and 3 days prior to inoculation with 2 mg
medoxyprogesterone (Depo-ProveraH, Pfizer Inc., New York),
which increases the efficiency of vaginal infection [54]. Immedi-
ately prior to HSV-2 inoculation, mice were anesthetized by i.p.
administration of xylazine (7 mg/kg) and ketamine (100 mg/kg).
Ocular inoculation of mice was performed by scarifying the left
and right corneas with a 26-gauge needle, blotting tear film from
the eyes with tissue paper, and by placing 4 ml complete DMEM
containing 25,000 pfu/ml of HSV-2 MS or HSV-2 0DNLS on
each scarified eye. Nasal inoculation of mice was achieved by
instilling 5 ml per nostril of the same 25,000 pfu/ml solution of
HSV-2 MS or 0DNLS from a micropipettor. For vaginal
inoculation, the vagina was cleared of mucus by briefly
introducing the cotton end of a cotton-tipped applicator into the
vagina. Upon removal of the cotton swab, a pipettor was used to
deliver 20 ml complete DMEM containing 25,000 pfu/ml of virus
into the vaginal vault.
Measurement of infectious HSV-2 titers in footpads,
ocular tearfilm, or vaginal mucosa
Viral titers in the footpads of mice were determined by
sacrificing mice at the indicated time, cutting the footpad off the
end of the limb into 0.5 ml complete DMEM, and homogenizing
the tissue with a Pro 200 homogenizer (Pro Scientific, Oxford,
CT). Viral titers were determined by a 12-well plate plaque assay
on ICP0-complementing L7 cells cultured in complete DMEM
containing 0.5% methlycellulose. Viral titers in ocular tear film or
the vaginal secretions of mice were determined at times after
inoculation by swabbing the eye with a cotton-tipped applicator or
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transferring the tip into 0.4 ml complete DMEM. Viral titers were
determined by a 96-well plate plaque assay on ICP0-complement-
ing L7 cells cultured in complete DMEM containing 0.5%
methlycellulose. After two to three days of incubation in each
plaque assay, cell monolayers were stained with a solution of 20%
methanol and 0.1% crystal violet and plaques were counted.
Purification of baculovirus-expressed gD-2 and GFP
The methods that were employed to express and purify
recombinant gD-2306t and GFP proteins from baculovirus-infected
insect cells are described, as follows.
i. Purification of gD-2306t antigen. The gD-2306t protein
engineered by Nicola, et al. (1996) possesses an N-terminal
honeybee melittin secretion signal in place of gD-2’s leader
peptide, followed by amino acids 1–306 of the mature gD-2
protein and a C-terminal His6 affinity-purification tag [34]. The
gD-2306t protein was isolated from a flask containing 2610
8 High
Five
TM insect cells that had been inoculated 48 hours earlier with
2 pfu per cell of gD-2306t -expressing baculovirus and incubated
while shaking at 27uC. Baculovirus-infected cells were removed by
centrifugation, and secreted gD-2306t protein was purifed from
supernatants by dialysis against an excess of 20 mM Tris pH 8.0,
300 mM NaCl, and 10% glycerol overnight. Imidazole was added
to the dialyzed supernatant to a concentration of 10 mM prior to
affinity purification on a HisTrap
TM HP column (GE Healthcare
Biosciences, Piscataway, NJ) using an A ¨KTApurifier
TM fast-
performance liquid chromatography system (GE Healthcare
Biosciences). The gD-2306t protein was eluted from the column
with 300 mM imidazole, and purity was verified at .90% by
SDS-PAGE and Coomassie blue staining. Aliquots of gD-2306t
were stored at 280uC until use.
ii. Purification of GFP (irrelevant) antigen. A C-terminal,
His-tagged GFPcodingsequencewas created byPCRamplification
off of a pEGFP-C1 plasmid (Clontech Laboratories, Mountain
View, CA), and was introduced into the pFastBacHtc vector
(Invitrogen Corporation, Carlsbad, CA) via Nco I and Xho I
restriction sites. A stock of His-GFP virus was constructed in Sf9
insect cells according to the manufacturer’s protocol. Recombinant
GFP protein was isolated from His-GFP-infected High Five
TM
insect cells per the same protocol used to isolate gD-2306t, except
that His-GFP-infected insect cells were harvested by centrifugation
48 hours post-infection, lysed, and the lysate was applied to a
HisTrap
TM HP column (GE Healthcare). Fractions containing
purified GFP (which were visibly lime-green) were combined,
aliquoted, and stored at 280uC until use.
Analysis of serum antibody responses to HSV-2 vaccines
Mice were bled on Day 50 or 60 post-inoculation by collecting
blood from the right retroorbital sinus with heparinized, Natelson
blood collecting tubes. The serum fraction was collected and
stored at 280uC until use in 1 of 4 assays for estimating the
abundance of HSV-2-specific antibody. Each method is described,
as follows.
i. gD-2-antibody-capture ELISA. High-binding EIA 96-well
plates (Costar, Corning, NY) were coated overnight at 4uC with
100 ml per well of sodium carbonate buffer (pH 9.6) containing
1.5 mg per ml gD-2306t protein [34]. Wells were blocked for 2 hours
with 400 ml of 2% dry milk dissolved in PBS+0.02% Tween-20
(polyoxyethylene-20-sorbitan monolaurate), hereafter referred to as
PBS-T buffer. Mouse serum was diluted 1:100 in PBS+1% fetal
bovine serum+0.02% Tween-20. After discarding blocking buffer
from ELISAplates, duplicate100-ml samplesof1:100 diluted mouse
serum were added to gD2306t -coated wells and were incubated for
2 hours. ELISA plates were rinsed seven times with an excess of
PBS-T buffer prior to the addition of 100 ml secondary antibody
diluted1:2500inPBS-Tbuffer; the secondaryantibody was alkaline
phosphatase-conjugated rabbit anti-mouse c chain (Rockland
Immunochemicals, Gilbertsville, PA). After allowing 1 hour,
secondary antibody was rinsed from plates seven times with PBS-
T buffer, and 200 m1 of p-nitrophenyl phosphate substrate (Sigma
Chemical Co., St. Louis, MO) was added to each well, and
colorimetric development (OD405) was measured after a 30 minute
incubation at room temperature.
ii. Antiserum-dependent neutralization of HSV-2 virion
infectivity. Two ml of each serum sample was added to a single
well inthe top rowof a microtiter plate containing91 ml ofcomplete
DMEM to achieve an initial 1:46 dilution. Serial 0.33-log dilutions
were achieved by serial transfer of 43 ml into 50 ml diluent (final
volume=93 ml) from the top to the bottom of the plate. A virus-
complement mixture was created by diluting guinea pig
complement (Rockland Immunochemicals, Gilbertsville, PA) 1:50
in complete DMEM and adding HSV-2 MS to a concentration of
3,500 pfu per ml. The HSV-2 neutralization assay was initiated by
combining 50 ml of the virus-complement mixture with each serum
dilution (50 ml) and incubating at 37uC. After 2 hours, 100 mlo fa
suspension containing 4610
6 Vero cells per ml was added to each
well, and microtiter plates were incubated for 48 hours to allow
HSV-2 plaques to form. Cell monolayers were fixed and stained
with a 20% methanol, 0.1% crystal violet solution. The HSV-2
neutralizing titer of each serum sample was considered to be the
reciprocal of the largest serum dilution that reduced HSV-2’s
cytopathic effect in Vero cell monolayers by at least 50%.
iii. Mouse antiserum-staining of HSV-2 plaques. Vero cell
monolayers were seeded in 12-well plates at a density of 5610
6 Vero
cellsandwereinoculated4 hourslaterwith40 pfuperwellofHSV-2
MS. At 32 hours p.i., Vero cell monolayers containing well-spaced
HSV-2 plaques were fixed for 20 minutes with a 2% formaldehyde-
2% sucrose solution and were permeabilized for 10 minutes with
90% methanol. HSV-1 Fc-c receptors (glycoprotein E-I
heterodimers; [89]) and non-specific-binding sites were blocked
with PBS containing 0.5% fetal bovine serum and 10 mg per ml each
of human c-globulin, donkey c-globulin, and goat c-globulin (PBS-F-
Ig). Fixed monolayers containing HSV-2 plaques were incubated for
6 hours with a 1:5,000 dilution of mouse antiserum, excess antibody
was removed with two rinses, and cells were incubated for 2 hours in
a 1:1,000 dilution of Alexa Fluor 594-conjugated goat antibody
specific for the Fc region of mouse IgG (Molecular Probes, Eugene,
OR).Excesssecondaryantibodywasremoved bytworinses,andcells
were photographed using a TE2000 inverted fluorescent microscope
(Nikon Instruments, Lewisville, TX) and DP72 digital camera
(Olympus America Inc., Center Valley, PA).
iv. Flow cytometric measurement of pan-HSV-2 IgG
antibody levels. Five 100 mm dishes of HSV-2 infected cells
were harvested 18 hours after inoculation with 2.5 pfu per cell.
Cells were trypsinized, resuspended in PBS+0.5% FBS (PBS-F),
centrifuged, and resuspended in 2% formaldehyde+2% sucrose for
20 minutes. Fixed cells were centrifuged, resuspended in 90%
methanol for 10 minutes, centrifuged, and resuspended in PBS-F.
Five dishes of uninfected Vero cells were identically processed in
parallel. Suspensions of fixed and permeabilized cells were passed
through 25 gauge needles to disperse cells into a uniform, single-
cell suspension. Cells were brought to a concentration of 5.6610
6
cells per ml in PBS-F-Ig block solution, and 90 ml aliquots of
uninfected or virus-infected cells were placed in a matched pair of
tubes containing 10 ml of each 1:500 dilution of pre-absorbed
mouse antiserum (i.e., 1:500 diluted serum was incubated
overnight with 0.5610
6 uninfected Vero cells). After a 6-hour
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centrifuged and rinsed twice with PBS-F to remove excess
mouse serum, and were then incubated with a 1:2,000 dilution
of allophycocyanin-conjugated goat antibody specific for the Fc
region of mouse IgG (Jackson Immunoresearch Laboratories, Inc.,
West Grove, PA). After 1 hour, excess secondary antibody was
removed by centrifugation and two rinses with PBS-F. Labeled
cells were analyzed in an Accuri C6 flow cytometer (Accuri
Cytometers, Inc., Ann Arbor, MI) using CFlow software (Accuri
Cytometers Inc.). Background fluorescence was defined as the
average mean fluorescent intensity (MFI) observed in uninfected
cell suspensions incubated with naı ¨ve serum. The relative
abundance of pan-HSV-2 IgG in serum was calculated as,
(MFI HSV-2 cells2MFI UI cells)4background (Fig. S4).
In the process of developing the flow cytometry-based assay, a
panel of 12 representative mouse serum samples was tested on 4
independent occasions. Within each of these serum samples, the
absolute estimate of pan-HSV-2 IgG abundance varied by an
average 30% between independent trials. However, the rank-order
of pan-HSV-2 IgG abundance was invariant among the 12
samples between independent trials.
In vivo imaging of HSV-2 MS-GFP and HSV-2 MS-
luciferase infections
i. HSV-2 MS-GFP challenge experiments. Fluorescent
photographs of the eyes and faces of mice inoculated with
100,000 pfu per eye of HSV-2 MS-GFP was visualized using a
TE2000 inverted fluorescent microscope (Nikon Instruments)
fitted with a DP72 digital camera (Olympus America). Mice
were anesthetized by i.p. administration of xylazine (6.6 mg/kg)
and ketamine (100 mg/kg) and placed face on a clear petri dish.
Photographs of the left side of mouse faces were obtained by
capturing 20 to 30 photographs with a 26objective that spanned
the face, and merging individual images using the photomerge
feature of Photoshop CS3 software (Adobe Systems Incorporated,
San Jose, CA).
ii. HSV-2 MS-luciferase challenge experiments. Luciferase
expression in mice inoculated with 100,000 pfu per eye or
500,000 pfu per vagina of HSV-2 MS-luciferase was visualized
using an IVISH Lumina II bioluminescent imager (Caliper
Instruments, Hopkinton, MA). Mice were anesthetized by i.p.
administration of xylazine (6.6 mg/kg) and ketamine (100 mg/kg),
injected with 3 mg D-luciferin substrate (Gold BioTechnology, Inc.,
St. Louis, MO), positioned inside the instrument, and a 120-second
exposure was captured. Longer and shorter exposures between 30
and300 secondsweretested,butthesehadnosignificanteffectonthe
relative differences between groups. Images were manipulated in
Living Image v3.1 software (Caliper Instruments), and were scaled in
a manner different than the default settings, specified as follows: 1.
binning (a signal : noise manipulation) was eliminated by setting to a
value of ‘1;’ 2. colored representations of light emissions were set to a
logarithmicscalewhichallowsvisualizationoftheentirerangeoflight
emissions detected by the instrument; and 3. the upper and lower
limits of the scale were always set to the same boundaries (1 to 1000)
such that the graphic representations of results were comparable
between tests. Finally, quantitation of light emission from HSV-2
MS-luciferase-challenged animals was calculated within the Living
Image v3.1 program (Figures6B and 6D) bycopying identically-sized
‘‘region of interest’’ boxes between Day 2, 4, and 6 measurements of
all experiments at the conclusion of the study.
Mathematical and statistical analysis of results
Viral titers were transformed by adding a value of 1 such that all
data could be analyzed on a logarithmic scale. The significance of
differences between multiple treatment groups was compared by
one-way analysis of variance (ANOVA) followed by Tukey’s post
hoc t-test. The data that was graphed and statistically compared
were the logarithms of i. HSV-2 shedding (e.g., pfu per vagina), ii.
gD-specific IgG abundance, iii. neutralizing antibody titer, iv.
pan-HSV-2 IgG levels. or v. luciferase activity (light emission) The
correlation (goodness-of-fit) between pan-HSV-2 antibody levels
and reductions in vaginal shedding following HSV-2 MS challenge
was evaluated by regression analysis. The significance of
differences in survival frequency between immunization groups
was determined by Fisher’s Exact Test. The significance of
differences in 0DNLS- versus gD-2-immunized mice was com-
pared by a two-sided, paired t-test for the following measurements:
i. reductions in HSV-2 vaginal shedding (Fig. 4C); ii. pan-HSV-2
IgG levels (Fig. 5C); iii. reductions in luciferase activity (Fig. 6).
The significance of differences in percent survival following HSV-
2 MS challenge of 0DNLS-immunized mice and gD-2-immunized
mice was compared by a two-sided Student’s t-test. Statistical
analyses were performed using Instat v3.0 software (Graphpad
Software, La Jolla, CA) and Microsoft Excel. The quantitative
relationship between color development in ELISA and abundance
of gD-specific IgG antibody was defined by a hyperbolic tangent-




, as described elsewhere [52,90].
Supporting Information
Figure S1 Shedding of HSV-2 MS and 0DNLS from the
site of inoculation. (A) HSV-2 shedding from the vaginas of
mice on Days 2 and 4 p.i. with 500,000 pfu per vagina of wild-type
HSV-2 MS or 0DNLS. (B) HSV-2 shedding from the eyes of mice
on Days 2 and 4 p.i. with 100,000 pfu per eye of HSV-2 MS or
0DNLS. A single asterisk (*) denotes p,0.05 and a double asterisk
(**) denotes p,0.001 that titers of HSV-2 0DNLS shed from the
vagina or eyes were equivalent to titers shed at the same site on the
same day by mice inoculated with HSV-2 MS.
(TIF)
Figure S2 Mice immunized with HSV-2 0DNLS are
resistant to HSV-2 ocular challenge. On Day 56 p.i.,
HSV-2 0DNLS- and MS-immunized mice were challenged with
100,000 pfu per eye of HSV-2 MS. (A) HSV-2 shedding from the
eyes between Days 1 and 3 post-challenge in naı ¨ve mice (n=10)
versus mice inoculated in the rear footpads with HSV-2 0DNLS
(n=5). (B) HSV-2 shedding from the eyes of naı ¨ve mice versus
mice inoculated in the eyes, nose, or vagina with HSV-2 0DNLS
(n=5 per group). A single asterisk (*) denotes p,0.05 and a
double asterisk (**) denotes p,0.001 that HSV-2 shedding was
equivalent to naı ¨ve controls on that day. (C) Survival frequency of
naı ¨ve mice (n=10) versus immunized mice (n=5 per group) one
month after HSV-2 challenge of the eyes. A double asterisk (**)
denotes p,0.001 that survival frequency was equivalent to naı ¨ve
mice.
(TIF)
Figure S3 Resistance of naı ¨ve versus immunized mice
to ocular HSV-2 infection. On Days 80, 90, or 100 p.i., mice
were challenged with 100,000 pfu per eye of HSV-2 MS (n=5 per
group). The summated results from all three experiments are
presented in each panel (gn=15 per group). (A) Ocular HSV-2
shedding between Days 1 and 7 post-challenge in naı ¨ve mice
(medium-treated) versus mice immunized with gD-21-306t or HSV-
20 DNLS. (B) Ocular HSV-2 shedding in naı ¨ve mice versus mice
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p,0.05 and a double asterisk (**) denotes p,0.001 that HSV-2
shedding was equivalent to naı ¨ve mice on that day. (C) Mean 6
sem reduction in HSV-2 shedding on Days 1–5 post-challenge
relative to the average titer of HSV-2 shed by naı ¨ve mice on that
day (n=605 per group). (D) Survival frequency over time
following HSV-2 MS challenge of the eyes. A double asterisk
(**) denotes p,0.001 that survival frequency was equivalent to
naı ¨ve mice.
(TIF)
Figure S4 Flow cytometry measurement of serum levels
of pan-HSV-2 IgG. (A) Summary of procedure. The immuno-
fluorescent background of each serum dilution was defined as the
average of the mean fluorescent intensity (MFI) of uninfected cell
suspensions incubated with that dilution of naı ¨ve serum. (B) Flow
cytometric analysis of 5-fold dilution series of antiserum samples
(n=3 samples per dilution).
(TIF)
Figure S5 Description of HSV-2 MS-GFP and HSV-2 MS-
luciferase. (A) Schematic of CMV-GFP and CMV-luciferase
expression cassettes introduced into the non-essential LAT gene of
HSV-2 MS-GFP and MS-luciferase, respectively. These gene
expression cassettes replaced bases 119,359–119,530 of the LAT
promoter. (B) Southern blot analysis of NotI-digested plasmid
DNA (shown on left) or NotI-digested viral DNA (shown on right).
The plasmid pUC-HSV-2-LAT contains the wild-type LAT gene.
The plasmids pUC-DLAT-GFP and pUC-DLAT-luciferase were
the plasmid precursors of HSV-2 MS-GFP and HSV-2 MS-
luciferase, respectively. NotI-digested cellular DNA was derived
from Vero cells that were uninfected (UI) or were harvested
18 hours after inoculation with 2.5 pfu per cell of HSV-2 MS,
MS-GFP, or MS-luciferase. A LAT promoter-specific oligonucle-
otide (59-ccctgtgtcattgtttacgtggccgcgggccagcagacgg-39) was hybrid-
ized to Southern blots, which hybridized upstream of the PvuII –
BspEI deletion in the LAT gene, and which verified that the gene
expression cassettes in pUC-DLAT-GFP and pUC-DLAT-lucifer-
ase were transferred into the intended locus in the HSV-2 genome.
(TIF)
Figure S6 Spread of HSV-2 MS-GFP infection between
Days 1 and 7 after challenge of naı ¨ve versus HSV-2
0DNLS-immunized mice. Progression of the spread of GFP
expression across the faces of naı ¨ve and 0DNLS-immunized mice
challenged with 100,000 pfu per eye of HSV-2 MS-GFP, as
visualized on Days 1, 3, 5, and 7 post-challenge. These
experiments were performed on n=3 mice per group, and the
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